FDA Mounjaro Heart Approval Shields Diabetes Reimbursement as Insurers Cut GLP-1 Coverage

Key points

• FDA approved Mounjaro on August 28, 2026, to lower heart attack, stroke, and cardiovascular death risks in high-risk type 2 diabetes adults.
• Employer coverage for GLP-1 weight-loss drugs dropped from 72% in 2025 to 60% in 2026, with 14% of employers planning cuts by 2027.
• Mounjaro Q2 revenue surged 91% to $9.94 billion, driven by volume growth despite a 9% U.S. price decline.
• The approval is based on the SURPASS-CVOT trial, which showed an 8% lower rate of major cardiovascular events compared to Trulicity.
• Lilly raised full-year revenue guidance to $85.0–$87.0 billion, with shares trading at $1,174.61.

Background

Eli Lilly has recently expanded its GLP-1 portfolio, including the UK approval of oral drug Foundayo and early access for retatrutide. The company has widened its market lead over Novo Nordisk, which faces growth concerns despite raising its own guidance.

How outlets are covering it

24/7 Wall St. emphasizes the strategic value of the new label for defending diabetes reimbursement against insurer pullbacks. Time notes the trial compared Mounjaro to an active drug (Trulicity) rather than a placebo, limiting direct comparisons to Novo Nordisk’s Ozempic. USA Today highlights that insurers are more likely to cover GLP-1s for diabetes or heart risk than for weight loss alone.

Why it matters

The approval provides Eli Lilly with a clinical justification to maintain reimbursement for diabetes patients, potentially stabilizing revenue as employers increasingly exclude GLP-1 drugs for weight management.

What to watch

Lilly is conducting a separate trial to assess Zepbound’s cardiovascular benefits in patients without diabetes, with results expected next year. Insurers will likely continue to differentiate coverage based on diabetes versus weight-loss indications.